Table 1 Clinical characteristics of patients with AML
Characteristic | Cases |
|---|---|
Sex | |
Male | 56 |
Female | 39 |
Age (years) | |
Range | 22-90 |
Median | 61 |
FAB subtype | |
M0 | 7 |
M1/M2 | 63 |
M4/M5 | 25 |
WBC (G/L) | |
Range | 0.2-295 |
Median | 14 |
HGB g% | |
Range | 5.8-13.1 |
Median | 9.3 |
PLT (G/L) | |
Range | 2-310 |
Median | 65 |
Lactate dehydrogenase (LDH) U/l | |
Range | 108-4565 |
Median | 340 |
Blasts in bone marrow | |
<50 % | 35 |
≥50 % | 60 |
Cytogenetics | |
Farorable | 5 |
Intermediate | 39 |
Unfavorable | 51 |
Chemotherapy | |
Intensive | 56 |
Low dose | 27 |
Best supportive care | 12 |
Molecular tests | Total 60 patients |
AML/ETO (positive/negative) | 4/56 |
CBFb-MYH11 (positive/negative) | 2/58 |
NPM1 (positive/negative) | 7/53 |
FLT3/ITD (positive/negative) | 13/47 |
Complete remission | |
Yes (total) | 51 |
Yes (after 1st line therapy) | 36 |
No | 44 |
Duration of remission (months) | |
Range | 2-54 |
Median | 20 |
Time to relapse (months) | |
Range | 3-23 |
Median | 12 |
Survival (months) | |
Range | 0-55 |
Median | 3 |